Harvard Bioscience (HBIO) Net Cash Flow (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Net Cash Flow data on file, last reported at -$1.3 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 217.47% year-over-year to -$1.3 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 25.93% increase from a year earlier, with the FY2025 full-year figure at $3.6 million, up 10314.29% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$1.3 million, down from $1.8 million in the prior quarter.
• Over the last five years, Net Cash Flow for HBIO reached as high as $1.8 million in Q4 2025 and fell as low as -$2.4 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$54764.7 across 5 years, with a median of -$98000.0 in 2024.
• On a YoY basis, Net Cash Flow climbed as much as 1889.8% in 2025 and fell as far as 458.94% in 2025.
• Year by year, Net Cash Flow stood at -$286000.0 in 2022, then slumped by 205.59% to -$874000.0 in 2023, then soared by 88.79% to -$98000.0 in 2024, then surged by 1889.8% to $1.8 million in 2025, then sank by 173.6% to -$1.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$1.3 million in Q1 2026, $1.8 million in Q4 2025, and -$542000.0 in Q3 2025.